Dulaglutide Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:

The clinical evidence base for Dulaglutide comprises 175 peer-reviewed publications across 15 journals, 18 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Body Weight Changes, and Polydipsia, Psychogenic. Most recent publication: Dulaglutide and neurodegeneration biomarkers: REWIND post hoc analysis., Alzheimers Dement, 2026.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

  1. Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial.
    Yabe D, Nakamura J, Kaneto H, et al. · Lancet Diabetes Endocrinol · 2020
    PubMed: PMID 32333876 · NCT03015220 (PIONEER 10) · Diabetes Mellitus, Type 2
  2. Cost of Achieving HbA1c Treatment Targets and Weight Loss Responses with Once-Weekly Semaglutide Versus Dulaglutide in the United States.
    Wilkinson L, Hunt B, Johansen P, et al. · Diabetes Ther · 2020
    PubMed: PMID 29557057 · NCT02648204 (SUSTAIN 7) · Diabetes Mellitus, Type 2
  3. Comparison of the injection-site experience of the starting doses with semaglutide and dulaglutide: A randomized, double-blind trial in healthy subjects.
    Snitker S, Andersen A, Berg B, et al. · Diabetes Obes Metab · 2021
    PubMed: PMID 33591618 · NCT04189848 · Diabetes Mellitus, Type 2
  4. Quantitative Assessment of Liver Fat with Magnetic Resonance Imaging and Spectroscopy.
    Reeder SB, Cruite I, Hamilton G, et al. · J Magn Reson Imaging · 2025
    PubMed: PMID 22025886 · NCT03590626 (D-LIFT) · Diabetes Mellitus, Type 2
  5. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial.
    Pratley RE, Aroda VR, Lingvay I, et al. · Lancet Diabetes Endocrinol · 2018
    PubMed: PMID 29397376 · NCT02648204 (SUSTAIN 7) · Diabetes Mellitus, Type 2
  6. Effect of Orally Administered Semaglutide Versus Dulaglutide on Diabetes-Related Quality of Life in Japanese Patients with Type 2 Diabetes: The PIONEER 10 Randomized, Active-Controlled Trial.
    Ishii H, Hansen BB, Langer J, et al. · Diabetes Ther · 2021
    PubMed: PMID 33460016 · NCT03015220 (PIONEER 10) · Diabetes Mellitus, Type 2
  7. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial.
    Dungan KM, Povedano ST, Forst T, et al. · Lancet · 2015
    PubMed: PMID 25018121 · NCT03590626 (D-LIFT) · Diabetes Mellitus, Type 2
  8. Effectiveness and Safety of GLP-1 Receptor Agonists in Patients with Type 1 Diabetes.
    Almohareb SN, Alfayez OM, Aljuaid SS, et al. · J Clin Med · 2024
    PubMed: PMID 39518671 · NCT07319286 · Menstruation Disturbances

Primary-outcome results across pivotal trials

Per-arm reported values from Phase 2/3 and Phase 3 trials with results posted to ClinicalTrials.gov.

TrialIndicationPrimary endpointArmValue
NCT01394952
REWIND
Diabetes Mellitus, Type 2Number of Participants Who Experienced an Event For Time, From Randomization to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (a Composite Cardiovascular Outcome)
From randomization to first occurrence or death from any cause or study completion (Median Follow-Up of 5.4 Years)
Dulaglutide594 Participants
Placebo663 Participants
NCT01621178
AWARD-7
Diabetes Mellitus, Type 2Change From Baseline in Hemoglobin A1c (HbA1c)
Baseline, 26 Weeks
Dulaglutide 0.75 mg-1.12 percentage of HbA1c (±0.12 Standard Error)
Dulaglutide 1.5 mg-1.19 percentage of HbA1c (±0.13 Standard Error)
Insulin Glargine-1.13 percentage of HbA1c (±0.12 Standard Error)
NCT01644500
AWARD-CHN1
Diabetes Mellitus, Type 2Change From Baseline in HbA1c at 26 Weeks
Baseline, 26 Weeks
0.75 mg Dulaglutide-1.22 percentage of HbA1c (±0.069 Standard Error)
1.5 mg Dulaglutide-1.48 percentage of HbA1c (±0.069 Standard Error)
Glimepiride-0.92 percentage of HbA1c (±0.069 Standard Error)
NCT01648582
AWARD-CHN2
Diabetes Mellitus, Type 2Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 26 Weeks
Baseline, 26 Weeks
0.75 mg Dulaglutide-1.33 percentage of HbA1c (±0.067 Standard Error)
1.5 mg Dulaglutide-1.73 percentage of HbA1c (±0.067 Standard Error)
Insulin Glargine-1.16 percentage of HbA1c (±0.067 Standard Error)
NCT01769378
AWARD-8
Diabetes Mellitus, Type 2Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at 24 Weeks
Baseline, 24 Weeks
Dulaglutide-1.38 percent change of HbA1c (±0.08 Standard Error)
Placebo-0.11 percent change of HbA1c (±0.14 Standard Error)
NCT02152371
AWARD-9
Diabetes Mellitus, Type 2Change From Baseline to 28 Weeks in Hemoglobin A1c (HbA1c)
Baseline, 28 Weeks
Dulaglutide + Insulin Glargine-1.44 percentage of change (±0.09 Standard Error)
Placebo + Insulin Glargine-0.67 percentage of change (±0.09 Standard Error)
NCT02597049
AWARD-10
Diabetes Mellitus, Type 2Change From Baseline in Hemoglobin A1c (HbA1c) at 24 Weeks (Treatment-regimen Estimand)
Baseline, Week 24
0.75 mg Dulaglutide-1.21 percentage of HbA1c (±0.064 Standard Error)
1.5 mg Dulaglutide-1.34 percentage of HbA1c (±0.064 Standard Error)
Placebo-0.54 percentage of HbA1c (±0.064 Standard Error)
NCT02597049
AWARD-10
Diabetes Mellitus, Type 2Change From Baseline in the HbA1c at 24 Weeks (Efficacy Estimand)
Baseline, Week 24
0.75 mg Dulaglutide-1.19 percentage of HbA1c (±0.063 Standard Error)
1.5 mg Dulaglutide-1.33 percentage of HbA1c (±0.063 Standard Error)
Placebo-0.51 percentage of HbA1c (±0.065 Standard Error)
NCT02648204
SUSTAIN 7
Diabetes Mellitus, Type 2Change in HbA1c
Week 0, week 40
Dulaglutide 0.75 mg-1.11 percentage of HbA1c (±0.05 Standard Error)
Dulaglutide 1.5 mg-1.37 percentage of HbA1c (±0.06 Standard Error)
Semaglutide 0.5 mg-1.51 percentage of HbA1c (±0.06 Standard Error)
Semaglutide 1.0 mg-1.78 percentage of HbA1c (±0.06 Standard Error)
NCT02787551
LixiLan-G
Diabetes Mellitus, Type 2Change From Baseline in Glycated Hemoglobin (HbA1c) to Week 26: Core Period
Baseline, Week 26
GLP-1 Receptor Agonist-0.38 percentage of HbA1c (±0.048 Standard Error)
Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC)-1.02 percentage of HbA1c (±0.048 Standard Error)
NCT02787551
LixiLan-G
Diabetes Mellitus, Type 2Change From Baseline in Glycated Hemoglobin (HbA1c) to Week 52: Single Arm Extension Period
Baseline, Week 52
Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC)-1.01 percentage of HbA1c (±0.063 Standard Error)
NCT02963766
AWARD-PEDS
Diabetes Mellitus, Type 2Change From Baseline in Hemoglobin A1c (HbA1c) (Pooled Doses) at Week 26
Baseline, Week 26
Placebo0.5 percentage of HbA1C (±0.24 Standard Error)
Pooled Dulaglutide-0.7 percentage of HbA1C (±0.16 Standard Error)
NCT03015220
PIONEER 10
Diabetes Mellitus, Type 2Number of Treatment-emergent Adverse Events (TEAEs)
Weeks 0-57
Dulaglutide 0.75 mg178 Events
Oral Semaglutide 14 mg324 Events
Oral Semaglutide 3 mg330 Events
Oral Semaglutide 7 mg350 Events
NCT03495102
AWARD-11
Diabetes Mellitus, Type 2Change in Hemoglobin A1c (HbA1c) From Baseline
Baseline, Week 36
Dulaglutide 1.5 mg-1.53 Percentage of HbA1c (±0.04 Standard Error)
Dulaglutide 3 mg-1.71 Percentage of HbA1c (±0.04 Standard Error)
Dulaglutide 4.5 mg-1.87 Percentage of HbA1c (±0.04 Standard Error)
NCT03684642
AMPLITUDE-D
Diabetes Mellitus, Type 2Change From Baseline to Week 56 in HbA1c
Baseline to Week 56
Dulaglutide 1.5 mg-1.09 percentage of HbA1c (±0.06 Standard Error)
Efpeglenatide 4 mg-1.12 percentage of HbA1c (±0.06 Standard Error)
Efpeglenatide 6 mg-1.17 percentage of HbA1c (±0.06 Standard Error)
NCT03861052
SURPASS J-mono
Diabetes Mellitus, Type 2Change From Baseline in Hemoglobin A1c (HbA1c)
Baseline, Week 52
0.75 mg Dulaglutide-1.29 percentage of HbA1c (±0.065 Standard Error)
10 mg Tirzepatide-2.55 percentage of HbA1c (±0.067 Standard Error)
15 mg Tirzepatide-2.82 percentage of HbA1c (±0.066 Standard Error)
5 mg Tirzepatide-2.37 percentage of HbA1c (±0.066 Standard Error)
NCT04591626
AWARD-CHN3
Diabetes Mellitus, Type 2Change From Baseline in Hemoglobin A1c (HbA1c)
Baseline, Week 28
1.5 mg Dulaglutide-2.03 Percentage of HbA1c (±0.076 Standard Error)
Placebo-1.08 Percentage of HbA1c (±0.073 Standard Error)
NCT04809220
AWARD-JPN
Diabetes Mellitus, Type 2Change From Baseline in Hemoglobin A1c (HbA1c) at Week 26
Baseline, Week 26
Dulaglutide 0.75 mg-1.25 Percentage of HbA1c (±0.060 Standard Error)
Dulaglutide 1.5 mg-1.53 Percentage of HbA1c (±0.043 Standard Error)

Publications by year

1992–2026: 175 publications.

1992
1
1998
1
2002
1
2004
1
2005
1
2006
1
2007
1
2009
2
2010
2
2011
3
2012
7
2013
3
2014
4
2015
7
2016
6
2017
6
2018
12
2019
14
2020
23
2021
24
2022
20
2023
11
2024
7
2025
12
2026
5

Publications by indication

Diabetes Mellitus, Type 2 (111)

  • Dulaglutide and neurodegeneration biomarkers: REWIND post hoc analysis.
    Alzheimers Dement · 2026 · PMID 41988866 · NCT01394952
  • Safety and efficacy of switching from dulaglutide to tirzepatide across clinically relevant baseline characteristics in participants with T2D: subgroup analysis of SURPASS-SWITCH.
    BMJ Open Diabetes Res Care · 2026 · PMID 41912265 · NCT05564039
  • Cardiorenal Outcomes With Tirzepatide Compared With Dulaglutide in Patients With Diabetes and Cardiovascular Disease: A Post Hoc Analysis of the SURPASS-CVOT Randomized Clinical Trial.
    JAMA Cardiol · 2026 · PMID 41903177 · NCT04255433
  • Cardiovascular outcomes of semaglutide and tirzepatide for patients with type 2 diabetes in clinical practice.
    Nat Med · 2026 · PMID 41207920 · NCT07088718
  • Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes.
    Nature · 2026 · PMID 41407860 · NCT05606913

Diabetes Mellitus, Type 1 (55)

  • More Time in Glucose Range During Exercise Days than Sedentary Days in Adults Living with Type 1 Diabetes.
    Diabetes Technol Ther · 2022 · PMID 33259257 · NCT05478707
  • Circulating biomarkers of nitric oxide bioactivity and impaired muscle vasoreactivity to exercise in adults with uncomplicated type 1 diabetes.
    Diabetologia · 2022 · PMID 33219433 · NCT05478707
  • Carotid-Femoral Pulse Wave Velocity as a Risk Marker for Development of Complications in Type 1 Diabetes Mellitus.
    J Am Heart Assoc · 2021 · PMID 32955366 · NCT05478707
  • Hyperglycemia But Not Hyperinsulinemia Is Favorable for Exercise in Type 1 Diabetes: A Pilot Study.
    Diabetes Care · 2021 · PMID 32661106 · NCT05478707
  • Association of Glycemic Indices (Hyperglycemia, Glucose Variability, and Hypoglycemia) with Oxidative Stress and Diabetic Complications.
    J Diabetes Res · 2021 · PMID 33123598 · NCT05478707

Body Weight Changes (6)

  • Blood pressure changes during smoking cessation in a randomized, double-blind, placebo-controlled trial of dulaglutide treatment.
    Eur J Prev Cardiol · 2025 · PMID 40037282 · NCT03204396
  • Effect of dulaglutide in promoting abstinence during smoking cessation: 12-month follow-up of a single-centre, randomised, double-blind, placebo-controlled, parallel group trial.
    EClinicalMedicine · 2024 · PMID 38371479 · NCT03204396
  • Gender differences in weight gain during attempted and successful smoking cessation on dulaglutide treatment: a predefined secondary analysis of a randomised trial.
    BMJ Nutr Prev Health · 2024 · PMID 38264360 · NCT03204396
  • Effects of dulaglutide on alcohol consumption during smoking cessation.
    JCI Insight · 2023 · PMID 37991022 · NCT03204396
  • Effect of dulaglutide in promoting abstinence during smoking cessation: a single-centre, randomized, double-blind, placebo-controlled, parallel group trial.
    EClinicalMedicine · 2023 · PMID 36874396 · NCT03204396

Polydipsia, Psychogenic (2)

  • Effect of a 3-Week Treatment with GLP-1 Receptor Agonists on Vasoactive Hormones in Euvolemic Participants.
    J Clin Endocrinol Metab · 2022 · PMID 35134170 · NCT02770885
  • A randomized controlled trial of the GLP-1 receptor agonist dulaglutide in primary polydipsia.
    J Clin Invest · 2021 · PMID 34473645 · NCT02770885

Menstruation Disturbances (1)

  • Effectiveness and Safety of GLP-1 Receptor Agonists in Patients with Type 1 Diabetes.
    J Clin Med · 2024 · PMID 39518671 · NCT07319286

Publications by journal

Trial-results highlights

In the NCT01394952 (REWIND) study, which evaluated a composite cardiovascular outcome (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) over a median follow-up of 5.4 years, **594 participants** in the **dulaglutide** arm experienced an event, compared to **663 participants** in the placebo arm.

Several studies evaluated the change from baseline in Hemoglobin A1c (HbA1c) for **dulaglutide** in type 2 diabetes mellitus. In NCT01621178 (AWARD-7), the change from baseline in HbA1c was:

  • Dulaglutide 0.75 mg: **-1.12 percentage of HbA1c**
  • Dulaglutide 1.5 mg: **-1.19 percentage of HbA1c**
  • Insulin Glargine: -1.13 percentage of HbA1c

In NCT01644500 (AWARD-CHN1), the change from baseline in HbA1c

All Dulaglutide publications (175)

2026 (5 papers)

  1. Dulaglutide and neurodegeneration biomarkers: REWIND post hoc analysis.
    Wilson JM, Dage JL, Qian HR, et al. · Alzheimers Dement · 2026 · Derived
    PubMed: PMID 41988866 · NCT01394952 (REWIND) · Diabetes Mellitus, Type 2
  2. Safety and efficacy of switching from dulaglutide to tirzepatide across clinically relevant baseline characteristics in participants with T2D: subgroup analysis of SURPASS-SWITCH.
    Violante-Ortiz R, Rose L, Sharma P, et al. · BMJ Open Diabetes Res Care · 2026 · Derived
    PubMed: PMID 41912265 · NCT05564039 (SURPASS-SWITCH) · Diabetes Mellitus, Type 2
  3. Cardiorenal Outcomes With Tirzepatide Compared With Dulaglutide in Patients With Diabetes and Cardiovascular Disease: A Post Hoc Analysis of the SURPASS-CVOT Randomized Clinical Trial.
    Nissen SE, Wolski K, D'Alessio D, et al. · JAMA Cardiol · 2026 · Derived
    PubMed: PMID 41903177 · NCT04255433 (SURPASS-CVOT) · Diabetes Mellitus, Type 2
  4. Cardiovascular outcomes of semaglutide and tirzepatide for patients with type 2 diabetes in clinical practice.
    Krüger N, Schneeweiss S, Desai RJ, et al. · Nat Med · 2026 · Derived
    PubMed: PMID 41207920 · NCT07088718 (DUP-SURPASS) · Diabetes Mellitus, Type 2
  5. Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes.
    Guo L, Zhang B, Xue X, et al. · Nature · 2026 · Derived
    PubMed: PMID 41407860 · NCT05606913 · Diabetes Mellitus, Type 2

2025 (12 papers)

  1. Quantitative Assessment of Liver Fat with Magnetic Resonance Imaging and Spectroscopy.
    Reeder SB, Cruite I, Hamilton G, et al. · J Magn Reson Imaging · 2025 · Trial result
    PubMed: PMID 22025886 · NCT03590626 (D-LIFT) · Diabetes Mellitus, Type 2
  2. Treatment with orforglipron, an oral glucagon like peptide-1 receptor agonist, is associated with improvements of CV risk biomarkers in participants with type 2 diabetes or obesity without diabetes.
    Wharton S, Rosenstock J, Konige M, et al. · Cardiovasc Diabetol · 2025 · Derived
    PubMed: PMID 40481478 · NCT05048719 · Diabetes Mellitus, Type 2
  3. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes.
    Nicholls SJ, Pavo I, Bhatt DL, et al. · N Engl J Med · 2025 · Derived
    PubMed: PMID 41406444 · NCT04255433 (SURPASS-CVOT) · Diabetes Mellitus, Type 2
  4. Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes.
    Natale P, Green SC, Tunnicliffe DJ, et al. · Cochrane Database Syst Rev · 2025 · Derived
    PubMed: PMID 39963952 · NCT01621178 (AWARD-7) · Diabetes Mellitus, Type 2
  5. Association Between Early Weight Loss and Metabolic Outcomes with Tirzepatide in Japanese Patients with Type 2 Diabetes: A SURPASS J Post Hoc Analysis.
    Mimura H, Oura T, Chin R, et al. · Diabetes Ther · 2025 · Derived
    PubMed: PMID 40711720 · NCT03861052 (SURPASS J-mono) · Diabetes Mellitus, Type 2
  6. Dulaglutide and Dapagliflozin Combination Concurrently Improves the Endothelial Glycocalyx and Vascular and Myocardial Function in Patients with T2DM and Albuminuria vs. DPP-4i.
    Korakas E, Thymis J, Oikonomou E, et al. · J Clin Med · 2025 · Derived
    PubMed: PMID 39768420 · NCT06611904 · Diabetes Mellitus, Type 2
  7. Weight Loss Efficacy of Tirzepatide Compared to Placebo or GLP-1 Receptor Agonists in Adults With Obesity or Overweight: A Meta-Analysis of Randomized Controlled Trials With ≥ 20 Weeks Treatment Duration.
    Khawaji A, A Jaly A, A Bakri H, et al. · J Obes · 2025 · Derived
    PubMed: PMID 40746703 · NCT04255433 (SURPASS-CVOT) · Diabetes Mellitus, Type 2
  8. Efficacy and safety of cAMP-biased GLP-1 receptor agonist ecnoglutide versus dulaglutide in patients with type 2 diabetes and elevated glucose concentrations on metformin monotherapy (EECOH-2): a 52-week, multicentre, open-label, non-inferiority, randomised, phase 3 trial.
    He Y, Mi N, Cheng Z, et al. · Lancet Diabetes Endocrinol · 2025 · Derived
    PubMed: PMID 40854315 · NCT05680129 · Diabetes Mellitus, Type 2
  9. Insulin Sensitivity and Beta-Cell Function Following Tirzepatide in Japanese Patients with Type 2 Diabetes: A SURPASS J-mono Analysis.
    Hamamoto Y, Oura T, Hirase T, et al. · Diabetes Ther · 2025 · Derived
    PubMed: PMID 39951042 · NCT03861052 (SURPASS J-mono) · Diabetes Mellitus, Type 2
  10. Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial.
    Coskun T, Wu Q, Schloot NC, et al. · Lancet Diabetes Endocrinol · 2025 · Derived
    PubMed: PMID 40609566 · NCT04867785 · Diabetes Mellitus, Type 2
  11. Comparison of Dose Escalation Versus Switching to Tirzepatide Among People With Type 2 Diabetes Inadequately Controlled on Lower Doses of Dulaglutide : A Randomized Clinical Trial.
    Billings LK, Winne L, Sharma P, et al. · Ann Intern Med · 2025 · Derived
    PubMed: PMID 40183678 · NCT05564039 (SURPASS-SWITCH) · Diabetes Mellitus, Type 2
  12. Blood pressure changes during smoking cessation in a randomized, double-blind, placebo-controlled trial of dulaglutide treatment.
    Beck J, Hasenböhler F, Werlen L, et al. · Eur J Prev Cardiol · 2025 · Derived
    PubMed: PMID 40037282 · NCT03204396 (SKIP) · Body Weight Changes

2024 (7 papers)

  1. Effectiveness and Safety of GLP-1 Receptor Agonists in Patients with Type 1 Diabetes.
    Almohareb SN, Alfayez OM, Aljuaid SS, et al. · J Clin Med · 2024 · Trial result
    PubMed: PMID 39518671 · NCT07319286 · Menstruation Disturbances
  2. Tirzepatide 5, 10 and 15 mg versus injectable semaglutide 0.5 mg for the treatment of type 2 diabetes: An adjusted indirect treatment comparison.
    Osumili B, Fan L, Paik JS, et al. · Diabetes Res Clin Pract · 2024 · Derived
    PubMed: PMID 38777128 · NCT02648204 (SUSTAIN 7) · Diabetes Mellitus, Type 2
  3. Metabolic Abnormalities Following Tirzepatide Monotherapy in Japanese Patients with Type 2 Diabetes: A Phase 3 SURPASS J-mono Post Hoc Analysis.
    Onishi Y, Oura T, Takeuchi M, et al. · Diabetes Ther · 2024 · Derived
    PubMed: PMID 38310163 · NCT03861052 (SURPASS J-mono) · Diabetes Mellitus, Type 2
  4. Effect of dulaglutide in promoting abstinence during smoking cessation: 12-month follow-up of a single-centre, randomised, double-blind, placebo-controlled, parallel group trial.
    Lüthi H, Lengsfeld S, Burkard T, et al. · EClinicalMedicine · 2024 · Derived
    PubMed: PMID 38371479 · NCT03204396 (SKIP) · Body Weight Changes
  5. Treatment Satisfaction and Quality of Life with Tirzepatide Versus Dulaglutide Among Japanese Patients with Type 2 Diabetes: Exploratory Evaluation of the SURPASS J-mono Trial.
    Ishii H, Oura T, Takeuchi M, et al. · Diabetes Ther · 2024 · Derived
    PubMed: PMID 37843771 · NCT03861052 (SURPASS J-mono) · Diabetes Mellitus, Type 2
  6. A pharmacokinetic study comparing the biosimilar HEC14028 and Dulaglutide (Trulicity®) in healthy Chinese subjects.
    Gao X, Di Y, Lv Y, et al. · Clin Transl Sci · 2024 · Derived
    PubMed: PMID 38651744 · NCT05459285 · Diabetes Mellitus, Type 2
  7. Gender differences in weight gain during attempted and successful smoking cessation on dulaglutide treatment: a predefined secondary analysis of a randomised trial.
    Baur F, Atila C, Lengsfeld S, et al. · BMJ Nutr Prev Health · 2024 · Derived
    PubMed: PMID 38264360 · NCT03204396 (SKIP) · Body Weight Changes

2023 (11 papers)

  1. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.
    Rosenstock J, Frias J, Jastreboff AM, et al. · Lancet · 2023 · Derived
    PubMed: PMID 37385280 · NCT04867785 · Diabetes Mellitus, Type 2
  2. Effects of dulaglutide on alcohol consumption during smoking cessation.
    Probst L, Monnerat S, Vogt DR, et al. · JCI Insight · 2023 · Derived
    PubMed: PMID 37991022 · NCT03204396 (SKIP) · Body Weight Changes
  3. Effect of dulaglutide in promoting abstinence during smoking cessation: a single-centre, randomized, double-blind, placebo-controlled, parallel group trial.
    Lengsfeld S, Burkard T, Meienberg A, et al. · EClinicalMedicine · 2023 · Derived
    PubMed: PMID 36874396 · NCT03204396 (SKIP) · Body Weight Changes
  4. Glucagon-like peptide-1 analogues: a new way to quit smoking? (SKIP)-a structured summary of a study protocol for a randomized controlled study.
    Lengsfeld S, Burkard T, Meienberg A, et al. · Trials · 2023 · Derived
    PubMed: PMID 37081574 · NCT03204396 (SKIP) · Body Weight Changes
  5. Phase 3 randomized, double-blind, sham-controlled Trial of e-TNS for the Acute treatment of Migraine (TEAM).
    Kuruvilla DE, Mann JI, Tepper SJ, et al. · Sci Rep · 2023 · Derived
    PubMed: PMID 35332216 · NCT02787551 (LixiLan-G) · Diabetes Mellitus, Type 2
  6. Biomarker Changes Associated With Both Dulaglutide and Cardiovascular Events in the REWIND Randomized Controlled Trial: A Nested Case-Control Post Hoc Analysis.
    Gerstein HC, Lee SF, Paré G, et al. · Diabetes Care · 2023 · Derived
    PubMed: PMID 36897834 · NCT01394952 (REWIND) · Diabetes Mellitus, Type 2
  7. Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study.
    Frias JP, Hsia S, Eyde S, et al. · Lancet · 2023 · Derived
    PubMed: PMID 37369232 · NCT05048719 · Diabetes Mellitus, Type 2
  8. Gender differences in cardiovascular risk, treatment, and outcomes: a post hoc analysis from the REWIND trial.
    Ferrannini G, Maldonado JM, Raha S, et al. · Scand Cardiovasc J · 2023 · Derived
    PubMed: PMID 36723445 · NCT01394952 (REWIND) · Diabetes Mellitus, Type 2
  9. Weight-dependent and weight-independent effects of dulaglutide on blood pressure in patients with type 2 diabetes.
    Ferdinand KC, Dunn J, Nicolay C, et al. · Cardiovasc Diabetol · 2023 · Derived
    PubMed: PMID 36894938 · NCT03495102 (AWARD-11) · Diabetes Mellitus, Type 2
  10. Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics.
    Nicholls SJ, Bhatt DL, Buse JB, et al. · Am Heart J · 2023 · Background
    PubMed: PMID 37758044 · NCT06779929 · Diabetes Mellitus, Type 2
  11. Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada.
    Johansen P, Håkan-Bloch J, Liu AR, et al. · Pharmacoecon Open · 2023 · Background
    PubMed: PMID 30927241 · NCT02648204 (SUSTAIN 7) · Diabetes Mellitus, Type 2

2022 (20 papers)

  1. Pharmacokinetics, Pharmacodynamics, and Safety of Dulaglutide After Single or Multiple Doses in Chinese Healthy Subjects and Patients with T2DM: A Randomized, Placebo-Controlled, Phase I Study.
    Xu J, Zhang Y, Li Y, et al. · Adv Ther · 2022 · Derived
    PubMed: PMID 34787823 · NCT01667900 · Diabetes Mellitus, Type 2
  2. Effect of a 3-Week Treatment with GLP-1 Receptor Agonists on Vasoactive Hormones in Euvolemic Participants.
    Vukajlovic T, Sailer CO, Asmar A, et al. · J Clin Endocrinol Metab · 2022 · Derived
    PubMed: PMID 35134170 · NCT02770885 (GOLD) · Polydipsia, Psychogenic
  3. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial.
    Urva S, Coskun T, Loh MT, et al. · Lancet · 2022 · Derived
    PubMed: PMID 36354040 · NCT04143802 · Diabetes Mellitus, Type 2
  4. Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis.
    Sattar N, McGuire DK, Pavo I, et al. · Nat Med · 2022 · Derived
    PubMed: PMID 35210595 · NCT03861052 (SURPASS J-mono) · Diabetes Mellitus, Type 2
  5. Effects of Tirzepatide, a Dual GIP and GLP-1 RA, on Lipid and Metabolite Profiles in Subjects With Type 2 Diabetes.
    Pirro V, Roth KD, Lin Y, et al. · J Clin Endocrinol Metab · 2022 · Derived
    PubMed: PMID 34608929 · NCT03131687 · Diabetes Mellitus, Type 2
  6. HbA1c Reduction in Dulaglutide-Treated Patients Irrespective of Duration of Diabetes, Microvascular Disease, and BMI: A Post Hoc Analysis From the REWIND Trial.
    Kwan AYM, Gerstein HC, Basile J, et al. · Diabetes Care · 2022 · Derived
    PubMed: PMID 35043140 · NCT01394952 (REWIND) · Diabetes Mellitus, Type 2
  7. Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND.
    Konig M, Riddle MC, Colhoun HM, et al. · Cardiovasc Diabetol · 2022 · Derived
    PubMed: PMID 34563178 · NCT01394952 (REWIND) · Diabetes Mellitus, Type 2
  8. Tirzepatide: A Novel, Once-weekly Dual GIP and GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes.
    Kaneko S · touchREV Endocrinol · 2022 · Derived
    PubMed: PMID 35949358 · NCT04255433 (SURPASS-CVOT) · Diabetes Mellitus, Type 2
  9. A phase 1b randomised controlled trial of a glucagon-like peptide-1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetes.
    Jiang H, Pang S, Zhang Y, et al. · Nat Commun · 2022 · Derived
    PubMed: PMID 35750681 · NCT04466904 · Diabetes Mellitus, Type 2
  10. Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial.
    Inagaki N, Takeuchi M, Oura T, et al. · Lancet Diabetes Endocrinol · 2022 · Derived
    PubMed: PMID 35914543 · NCT03861052 (SURPASS J-mono) · Diabetes Mellitus, Type 2
  11. Concomitant iGlarLixi and Sodium-Glucose Co-transporter-2 Inhibitor Therapy in Adults with Type 2 Diabetes: LixiLan-G Trial and Real-World Evidence Results.
    Guja C, Giorgino F, Blonde L, et al. · Diabetes Ther · 2022 · Derived
    PubMed: PMID 34894329 · NCT02787551 (LixiLan-G) · Diabetes Mellitus, Type 2
  12. A novel kidney disease index reflecting both the albumin-to-creatinine ratio and estimated glomerular filtration rate, predicted cardiovascular and kidney outcomes in type 2 diabetes.
    Gerstein HC, Ramasundarahettige C, Avezum A, et al. · Cardiovasc Diabetol · 2022 · Derived
    PubMed: PMID 35996147 · NCT01394952 (REWIND) · Diabetes Mellitus, Type 2
  13. Efficacy and safety outcomes of dulaglutide by baseline HbA1c: A post hoc analysis of the REWIND trial.
    Franek E, Gerstein HC, Riddle MC, et al. · Diabetes Obes Metab · 2022 · Derived
    PubMed: PMID 35546279 · NCT01394952 (REWIND) · Diabetes Mellitus, Type 2
  14. Fixed-ratio combination of insulin glargine plus lixisenatide (iGlarLixi) improves ß-cell function in people with type 2 diabetes.
    Ferrannini E, Niemoeller E, Dex T, et al. · Diabetes Obes Metab · 2022 · Derived
    PubMed: PMID 35257461 · NCT02787551 (LixiLan-G) · Diabetes Mellitus, Type 2
  15. Novel Indices of Cognitive Impairment and Incident Cardiovascular Outcomes in the REWIND Trial.
    Cukierman-Yaffe T, Gerstein HC, Basile J, et al. · J Clin Endocrinol Metab · 2022 · Derived
    PubMed: PMID 35446415 · NCT01394952 (REWIND) · Diabetes Mellitus, Type 2
  16. Effect of expanded dulaglutide weekly doses (3.0 mg and 4.5 mg) on cardiovascular disease risk factors in participants with type 2 diabetes at increased cardiovascular disease risk: a post hoc analysis of the AWARD-11 study.
    Cox DA, Wang H, Nicolay C, et al. · Diabetes Obes Metab · 2022 · Derived
    PubMed: PMID 35546790 · NCT03495102 (AWARD-11) · Diabetes Mellitus, Type 2
  17. Effects of GLP-1 Receptor Agonists on Bone Mineral Density in Patients with Type 2 Diabetes Mellitus: A 52-Week Clinical Study.
    Cai TT, Li HQ, Jiang LL, et al. · Biomed Res Int · 2022 · Derived
    PubMed: PMID 34580638 · NCT01648582 (AWARD-CHN2) · Diabetes Mellitus, Type 2
  18. Once-Weekly Dulaglutide for the Treatment of Youths with Type 2 Diabetes.
    Arslanian SA, Hannon T, Zeitler P, et al. · N Engl J Med · 2022 · Derived
    PubMed: PMID 35658022 · NCT02963766 (AWARD-PEDS) · Diabetes Mellitus, Type 2
  19. More Time in Glucose Range During Exercise Days than Sedentary Days in Adults Living with Type 1 Diabetes.
    Riddell MC, Li Z, Beck RW, et al. · Diabetes Technol Ther · 2022 · Background
    PubMed: PMID 33259257 · NCT05478707 (KML002) · Diabetes Mellitus, Type 1
  20. Circulating biomarkers of nitric oxide bioactivity and impaired muscle vasoreactivity to exercise in adults with uncomplicated type 1 diabetes.
    Lespagnol E, Tagougui S, Fernandez BO, et al. · Diabetologia · 2022 · Background
    PubMed: PMID 33219433 · NCT05478707 (KML002) · Diabetes Mellitus, Type 1

2021 (24 papers)

  1. Comparison of the injection-site experience of the starting doses with semaglutide and dulaglutide: A randomized, double-blind trial in healthy subjects.
    Snitker S, Andersen A, Berg B, et al. · Diabetes Obes Metab · 2021 · Trial result
    PubMed: PMID 33591618 · NCT04189848 · Diabetes Mellitus, Type 2
  2. Effect of Orally Administered Semaglutide Versus Dulaglutide on Diabetes-Related Quality of Life in Japanese Patients with Type 2 Diabetes: The PIONEER 10 Randomized, Active-Controlled Trial.
    Ishii H, Hansen BB, Langer J, et al. · Diabetes Ther · 2021 · Trial result
    PubMed: PMID 33460016 · NCT03015220 (PIONEER 10) · Diabetes Mellitus, Type 2
  3. Pancreatic Safety of Once-Weekly Dulaglutide in Chinese Patients with Type 2 Diabetes Mellitus: Subgroup Analysis by Potential Influencing Factors.
    Zhou Y, Zhu J, Wu H, et al. · Diabetes Ther · 2021 · Derived
    PubMed: PMID 34453682 · NCT01648582 (AWARD-CHN2) · Diabetes Mellitus, Type 2
  4. A randomized controlled trial of the GLP-1 receptor agonist dulaglutide in primary polydipsia.
    Winzeler B, Sailer CO, Coynel D, et al. · J Clin Invest · 2021 · Derived
    PubMed: PMID 34473645 · NCT02770885 (GOLD) · Polydipsia, Psychogenic
  5. Efficacy, safety and cardiovascular outcomes of once-daily oral semaglutide in patients with type 2 diabetes: The PIONEER programme.
    Thethi TK, Pratley R, Meier JJ, et al. · Diabetes Obes Metab · 2021 · Derived
    PubMed: PMID 32267058 · NCT03015220 (PIONEER 10) · Diabetes Mellitus, Type 2
  6. Efficacy and Safety of Dulaglutide in Older Patients: A post hoc Analysis of the REWIND trial.
    Riddle MC, Gerstein HC, Xavier D, et al. · J Clin Endocrinol Metab · 2021 · Derived
    PubMed: PMID 33537745 · NCT01394952 (REWIND) · Diabetes Mellitus, Type 2
  7. Impact of patient characteristics on efficacy and safety of once-weekly semaglutide versus dulaglutide: SUSTAIN 7 post hoc analyses.
    Pratley RE, Aroda VR, Catarig AM, et al. · BMJ Open · 2021 · Derived
    PubMed: PMID 33199417 · NCT02648204 (SUSTAIN 7) · Diabetes Mellitus, Type 2
  8. Efficacy and Safety of Once Weekly Dulaglutide in East Asian Patients with Type 2 Diabetes: Subgroup Analysis by Potential Influential Factors.
    Ma J, Zhang B, Hou J, et al. · Diabetes Ther · 2021 · Derived
    PubMed: PMID 33161492 · NCT01648582 (AWARD-CHN2) · Diabetes Mellitus, Type 2
  9. Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial).
    Kuchay MS, Krishan S, Mishra SK, et al. · Diabetologia · 2021 · Derived
    PubMed: PMID 32865597 · NCT03590626 (D-LIFT) · Diabetes Mellitus, Type 2
  10. Efficacy and Safety of Once-Weekly Dulaglutide in Elderly Chinese Patients with Type 2 Diabetes: A Post Hoc Analysis of AWARD-CHN Studies.
    Kuang J, Zhu J, Liu S, et al. · Diabetes Ther · 2021 · Derived
    PubMed: PMID 32857293 · NCT01644500 (AWARD-CHN1) · Diabetes Mellitus, Type 2
  11. Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk.
    Husain M, Bain SC, Jeppesen OK, et al. · Diabetes Obes Metab · 2021 · Derived
    PubMed: PMID 31903692 · NCT03015220 (PIONEER 10) · Diabetes Mellitus, Type 2
  12. Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials.
    Husain M, Bain SC, Holst AG, et al. · Cardiovasc Diabetol · 2021 · Derived
    PubMed: PMID 32998732 · NCT03015220 (PIONEER 10) · Diabetes Mellitus, Type 2
  13. Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes.
    Hartman ML, Sanyal AJ, Loomba R, et al. · Diabetes Care · 2021 · Derived
    PubMed: PMID 32291277 · NCT03131687 · Diabetes Mellitus, Type 2
  14. Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11).
    Frias JP, Bonora E, Nevarez Ruiz L, et al. · Diabetes Care · 2021 · Derived
    PubMed: PMID 33397768 · NCT03495102 (AWARD-11) · Diabetes Mellitus, Type 2
  15. Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis.
    Dagenais GR, Rydén L, Leiter LA, et al. · Cardiovasc Diabetol · 2021 · Derived
    PubMed: PMID 33239067 · NCT01394952 (REWIND) · Diabetes Mellitus, Type 2
  16. Durable Effects of iGlarLixi Up to 52 Weeks in Type 2 Diabetes: The LixiLan-G Extension Study.
    Blonde L, Rosenstock J, Frias J, et al. · Diabetes Care · 2021 · Derived
    PubMed: PMID 33468520 · NCT02787551 (LixiLan-G) · Diabetes Mellitus, Type 2
  17. Erectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trial.
    Bajaj HS, Gerstein HC, Rao-Melacini P, et al. · Lancet Diabetes Endocrinol · 2021 · Derived
    PubMed: PMID 34153269 · NCT01394952 (REWIND) · Diabetes Mellitus, Type 2
  18. Carotid-Femoral Pulse Wave Velocity as a Risk Marker for Development of Complications in Type 1 Diabetes Mellitus.
    Tougaard NH, Theilade S, Winther SA, et al. · J Am Heart Assoc · 2021 · Background
    PubMed: PMID 32955366 · NCT05478707 (KML002) · Diabetes Mellitus, Type 1
  19. Hyperglycemia But Not Hyperinsulinemia Is Favorable for Exercise in Type 1 Diabetes: A Pilot Study.
    Romeres D, Olson K, Carter R, et al. · Diabetes Care · 2021 · Background
    PubMed: PMID 32661106 · NCT05478707 (KML002) · Diabetes Mellitus, Type 1
  20. Association of Glycemic Indices (Hyperglycemia, Glucose Variability, and Hypoglycemia) with Oxidative Stress and Diabetic Complications.
    Papachristoforou E, Lambadiari V, Maratou E, et al. · J Diabetes Res · 2021 · Background
    PubMed: PMID 33123598 · NCT05478707 (KML002) · Diabetes Mellitus, Type 1
  21. Assessing patient PREFERence between the dulaglutide pen and the semaglutide pen: A crossover study (PREFER).
    Matza LS, Boye KS, Stewart KD, et al. · Diabetes Obes Metab · 2021 · Background
    PubMed: PMID 31646727 · NCT03724981 · Diabetes Mellitus, Type 2
  22. Insulin-mediated muscle microvascular perfusion and its phenotypic predictors in humans.
    Love KM, Jahn LA, Hartline LM, et al. · Sci Rep · 2021 · Background
    PubMed: PMID 34075130 · NCT05478707 (KML002) · Diabetes Mellitus, Type 1
  23. A single bout of exercise improves vascular insulin sensitivity in adults with obesity.
    Heiston EM, Liu Z, Ballantyne A, et al. · Obesity (Silver Spring) · 2021 · Background
    PubMed: PMID 34339111 · NCT05478707 (KML002) · Diabetes Mellitus, Type 1
  24. Differences in Physiological Responses to Cardiopulmonary Exercise Testing in Adults With and Without Type 1 Diabetes: A Pooled Analysis.
    Eckstein ML, Farinha JB, McCarthy O, et al. · Diabetes Care · 2021 · Background
    PubMed: PMID 33184152 · NCT05478707 (KML002) · Diabetes Mellitus, Type 1

2020 (23 papers)

  1. Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial.
    Yabe D, Nakamura J, Kaneto H, et al. · Lancet Diabetes Endocrinol · 2020 · Trial result
    PubMed: PMID 32333876 · NCT03015220 (PIONEER 10) · Diabetes Mellitus, Type 2
  2. Cost of Achieving HbA1c Treatment Targets and Weight Loss Responses with Once-Weekly Semaglutide Versus Dulaglutide in the United States.
    Wilkinson L, Hunt B, Johansen P, et al. · Diabetes Ther · 2020 · Trial result
    PubMed: PMID 29557057 · NCT02648204 (SUSTAIN 7) · Diabetes Mellitus, Type 2
  3. Evaluation of the long-term cost-effectiveness of once-weekly semaglutide versus dulaglutide for treatment of type 2 diabetes mellitus in the UK.
    Viljoen A, Hoxer CS, Johansen P, et al. · Diabetes Obes Metab · 2020 · Trial result
    PubMed: PMID 30362224 · NCT02648204 (SUSTAIN 7) · Diabetes Mellitus, Type 2
  4. Effects of Different Antidiabetic Medications on Endothelial Glycocalyx, Myocardial Function, and Vascular Function in Type 2 Diabetic Patients: One Year Follow-Up Study.
    Lambadiari V, Pavlidis G, Kousathana F, et al. · J Clin Med · 2020 · Trial result
    PubMed: PMID 31284526 · NCT06611904 · Diabetes Mellitus, Type 2
  5. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials.
    Aroda VR, Ahmann A, Cariou B, et al. · Diabetes Metab · 2020 · Trial result
    PubMed: PMID 30615985 · NCT02648204 (SUSTAIN 7) · Diabetes Mellitus, Type 2
  6. Efficacy and Safety of Dulaglutide by Baseline HbA1c in Chinese Patients with Type 2 Diabetes: A Post Hoc Analysis.
    Yu M, Yuan GY, Zhang B, et al. · Diabetes Ther · 2020 · Derived
    PubMed: PMID 32277401 · NCT01644500 (AWARD-CHN1) · Diabetes Mellitus, Type 2
  7. The Effects of Once-Weekly Dulaglutide and Insulin Glargine on Glucose Fluctuation in Poorly Oral-Antidiabetic Controlled Patients with Type 2 Diabetes Mellitus.
    Wang J, Li HQ, Xu XH, et al. · Biomed Res Int · 2020 · Derived
    PubMed: PMID 31950036 · NCT01648582 (AWARD-CHN2) · Diabetes Mellitus, Type 2
  8. Efficacy and Safety of Once-Weekly Dulaglutide in Type 2 Diabetes Patients Using Insulin: Exploratory Subgroup Analysis by Insulin Regimen.
    Onishi Y, Ishii H, Oura T, et al. · Diabetes Ther · 2020 · Derived
    PubMed: PMID 31994009 · NCT02750410 · Diabetes Mellitus, Type 2
  9. Efficacy and Safety of Dulaglutide Monotherapy Compared to Glimepiride in Oral Antihyperglycemic Medication-Naïve Chinese patients with Type 2 Diabetes: A Post Hoc Analysis of AWARD-CHN1.
    Li YM, Zhang LH, Li XJ, et al. · Diabetes Ther · 2020 · Derived
    PubMed: PMID 32219675 · NCT01644500 (AWARD-CHN1) · Diabetes Mellitus, Type 2
  10. Efficacy and Safety of Dulaglutide Versus Insulin Glargine in Chinese T2DM Patients: A Subgroup Analysis of a Randomized Trial (AWARD-CHN2).
    Li Y, Li L, De Peng Y, et al. · Diabetes Ther · 2020 · Derived
    PubMed: PMID 31228090 · NCT01648582 (AWARD-CHN2) · Diabetes Mellitus, Type 2
  11. A Randomized Study to Compare the Effects of Once-Weekly Dulaglutide Injection and Once-Daily Glimepiride on Glucose Fluctuation of Type 2 Diabetes Mellitus Patients: A 26-Week Follow-Up.
    Li H, Xu X, Wang J, et al. · J Diabetes Res · 2020 · Derived
    PubMed: PMID 31183384 · NCT01644500 (AWARD-CHN1) · Diabetes Mellitus, Type 2
  12. Improved treatment satisfaction in patients with type 2 diabetes treated with once-weekly semaglutide in the SUSTAIN trials.
    Jendle J, Birkenfeld AL, Polonsky WH, et al. · Diabetes Obes Metab · 2020 · Derived
    PubMed: PMID 31215727 · NCT02648204 (SUSTAIN 7) · Diabetes Mellitus, Type 2
  13. Once-Weekly Dulaglutide with Insulin Therapy for Type 2 Diabetes: Efficacy and Safety Results from a Phase 4, Randomized, Placebo-Controlled Study.
    Ishii H, Onishi Y, Oura T, et al. · Diabetes Ther · 2020 · Derived
    PubMed: PMID 31758520 · NCT02750410 · Diabetes Mellitus, Type 2
  14. Effect of Once-Weekly Dulaglutide on Glucose Levels in Japanese Patients with Type 2 Diabetes: Findings from a Phase 4, Randomized Controlled Trial.
    Inoue M, Shiramoto M, Oura T, et al. · Diabetes Ther · 2020 · Derived
    PubMed: PMID 30949907 · NCT03315780 · Diabetes Mellitus, Type 2
  15. Evaluation of Characteristics of Gastrointestinal Adverse Events with Once-Weekly Dulaglutide Treatment in Chinese Patients with Type 2 Diabetes: A Post Hoc Pooled Analysis of Two Randomized Trials.
    Guo L, Zhang B, Hou J, et al. · Diabetes Ther · 2020 · Derived
    PubMed: PMID 32621083 · NCT01648582 (AWARD-CHN2) · Diabetes Mellitus, Type 2
  16. The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial.
    Gerstein HC, Hart R, Colhoun HM, et al. · Lancet Diabetes Endocrinol · 2020 · Derived
    PubMed: PMID 31924562 · NCT01394952 (REWIND) · Diabetes Mellitus, Type 2
  17. Efficacy and Safety of Semaglutide for Type 2 Diabetes by Race and Ethnicity: A Post Hoc Analysis of the SUSTAIN Trials.
    DeSouza C, Cariou B, Garg S, et al. · J Clin Endocrinol Metab · 2020 · Derived
    PubMed: PMID 31769496 · NCT02648204 (SUSTAIN 7) · Diabetes Mellitus, Type 2
  18. Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial.
    Cukierman-Yaffe T, Gerstein HC, Colhoun HM, et al. · Lancet Neurol · 2020 · Derived
    PubMed: PMID 32562683 · NCT01394952 (REWIND) · Diabetes Mellitus, Type 2
  19. Switching to iGlarLixi Versus Continuing Daily or Weekly GLP-1 RA in Type 2 Diabetes Inadequately Controlled by GLP-1 RA and Oral Antihyperglycemic Therapy: The LixiLan-G Randomized Clinical Trial.
    Blonde L, Rosenstock J, Del Prato S, et al. · Diabetes Care · 2020 · Derived
    PubMed: PMID 31530665 · NCT02787551 (LixiLan-G) · Diabetes Mellitus, Type 2
  20. Vasodilatory Actions of Glucagon-Like Peptide 1 Are Preserved in Skeletal and Cardiac Muscle Microvasculature but Not in Conduit Artery in Obese Humans With Vascular Insulin Resistance.
    Wang N, Tan AWK, Jahn LA, et al. · Diabetes Care · 2020 · Background
    PubMed: PMID 31888883 · NCT05478707 (KML002) · Diabetes Mellitus, Type 1
  21. Endothelial dysfunction due to selective insulin resistance in vascular endothelium: insights from mechanistic modeling.
    Muniyappa R, Chen H, Montagnani M, et al. · Am J Physiol Endocrinol Metab · 2020 · Background
    PubMed: PMID 32776829 · NCT05478707 (KML002) · Diabetes Mellitus, Type 1
  22. The Management of Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide: A Long-Term Cost-Effectiveness Analysis in Slovakia.
    Malkin SJP, Russel-Szymczyk M, Psota M, et al. · Adv Ther · 2020 · Background
    PubMed: PMID 31168765 · NCT02648204 (SUSTAIN 7) · Diabetes Mellitus, Type 2
  23. Superior Effects of High-Intensity Interval vs. Moderate-Intensity Continuous Training on Endothelial Function and Cardiorespiratory Fitness in Patients With Type 1 Diabetes: A Randomized Controlled Trial.
    Boff W, da Silva AM, Farinha JB, et al. · Front Physiol · 2020 · Background
    PubMed: PMID 31110479 · NCT05478707 (KML002) · Diabetes Mellitus, Type 1

2019 (14 papers)

  1. Comparative efficacy of once-weekly semaglutide and SGLT-2 inhibitors in type 2 diabetic patients inadequately controlled with metformin monotherapy: a systematic literature review and network meta-analysis.
    Sharma R, Wilkinson L, Vrazic H, et al. · Curr Med Res Opin · 2019 · Trial result
    PubMed: PMID 29764222 · NCT02648204 (SUSTAIN 7) · Diabetes Mellitus, Type 2
  2. Effects of 6-month treatment with the glucagon like peptide-1 analogue liraglutide on arterial stiffness, left ventricular myocardial deformation and oxidative stress in subjects with newly diagnosed type 2 diabetes.
    Lambadiari V, Pavlidis G, Kousathana F, et al. · Cardiovasc Diabetol · 2019 · Trial result
    PubMed: PMID 29310645 · NCT06611904 · Diabetes Mellitus, Type 2
  3. Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials enrollment criteria to the US type 2 diabetes population.
    Wittbrodt ET, Eudicone JM, Bell KF, et al. · Am J Manag Care · 2019 · Derived
    PubMed: PMID 29693361 · NCT01394952 (REWIND) · Diabetes Mellitus, Type 2
  4. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial.
    Tuttle KR, Lakshmanan MC, Rayner B, et al. · Lancet Diabetes Endocrinol · 2019 · Derived
    PubMed: PMID 29910024 · NCT01621178 (AWARD-7) · Diabetes Mellitus, Type 2
  5. Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial.
    Ludvik B, Frías JP, Tinahones FJ, et al. · Lancet Diabetes Endocrinol · 2019 · Derived
    PubMed: PMID 29483060 · NCT02597049 (AWARD-10) · Diabetes Mellitus, Type 2
  6. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
    Gerstein HC, Colhoun HM, Dagenais GR, et al. · Lancet · 2019 · Derived
    PubMed: PMID 31189511 · NCT01394952 (REWIND) · Diabetes Mellitus, Type 2
  7. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial.
    Gerstein HC, Colhoun HM, Dagenais GR, et al. · Lancet · 2019 · Derived
    PubMed: PMID 31189509 · NCT01394952 (REWIND) · Diabetes Mellitus, Type 2
  8. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
    Frias JP, Nauck MA, Van J, et al. · Lancet · 2019 · Derived
    PubMed: PMID 30293770 · NCT03131687 · Diabetes Mellitus, Type 2
  9. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.
    Coskun T, Sloop KW, Loghin C, et al. · Mol Metab · 2019 · Derived
    PubMed: PMID 30473097 · NCT02759107 · Diabetes Mellitus, Type 2
  10. High-Intensity Interval Training Improves Aerobic Capacity Without a Detrimental Decline in Blood Glucose in People With Type 1 Diabetes.
    Scott SN, Cocks M, Andrews RC, et al. · J Clin Endocrinol Metab · 2019 · Background
    PubMed: PMID 30281094 · NCT05478707 (KML002) · Diabetes Mellitus, Type 1
  11. GREATER COMBINED REDUCTIONS IN HbA1C ≥1.0% AND WEIGHT ≥5.0% WITH SEMAGLUTIDE VERSUS COMPARATORS IN TYPE 2 DIABETES.
    Rodbard HW, Bellary S, Hramiak I, et al. · Endocr Pract · 2019 · Background
    PubMed: PMID 30865526 · NCT02648204 (SUSTAIN 7) · Diabetes Mellitus, Type 2
  12. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.
    Hernandez AF, Green JB, Janmohamed S, et al. · Lancet · 2019 · Background
    PubMed: PMID 30291013 · NCT05478707 (KML002) · Diabetes Mellitus, Type 1
  13. State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016-2018.
    Foster NC, Beck RW, Miller KM, et al. · Diabetes Technol Ther · 2019 · Background
    PubMed: PMID 30657336 · NCT05478707 (KML002) · Diabetes Mellitus, Type 1
  14. Glycemic, inflammatory and oxidative stress responses to different high-intensity training protocols in type 1 diabetes: A randomized clinical trial.
    Farinha JB, Ramis TR, Vieira AF, et al. · J Diabetes Complications · 2019 · Background
    PubMed: PMID 30270019 · NCT05478707 (KML002) · Diabetes Mellitus, Type 1

2018 (12 papers)

  1. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial.
    Pratley RE, Aroda VR, Lingvay I, et al. · Lancet Diabetes Endocrinol · 2018 · Trial result
    PubMed: PMID 29397376 · NCT02648204 (SUSTAIN 7) · Diabetes Mellitus, Type 2
  2. Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial.
    Ahmann AJ, Capehorn M, Charpentier G, et al. · Diabetes Care · 2018 · Trial result
    PubMed: PMID 29246950 · NCT02648204 (SUSTAIN 7) · Diabetes Mellitus, Type 2
  3. Patient-reported Outcomes in Patients with Type 2 Diabetes Treated with Dulaglutide Added to Titrated Insulin Glargine (AWARD-9).
    Yu M, Brunt KV, Milicevic Z, et al. · Clin Ther · 2018 · Derived
    PubMed: PMID 29110972 · NCT02152371 (AWARD-9) · Diabetes Mellitus, Type 2
  4. Dulaglutide 1.5 mg as an add-on option for patients uncontrolled on insulin: Subgroup analysis by age, duration of diabetes and baseline glycated haemoglobin concentration.
    Pantalone KM, Patel H, Yu M, et al. · Diabetes Obes Metab · 2018 · Derived
    PubMed: PMID 29430801 · NCT02152371 (AWARD-9) · Diabetes Mellitus, Type 2
  5. Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide.
    Gerstein HC, Colhoun HM, Dagenais GR, et al. · Diabetes Obes Metab · 2018 · Derived
    PubMed: PMID 28573765 · NCT01394952 (REWIND) · Diabetes Mellitus, Type 2
  6. No Dose Adjustment is Recommended for Digoxin, Warfarin, Atorvastatin or a Combination Oral Contraceptive When Coadministered with Dulaglutide.
    de la Peña A, Cui X, Geiser J, et al. · Clin Pharmacokinet · 2018 · Derived
    PubMed: PMID 28357715 · NCT01436201 · Diabetes Mellitus, Type 2
  7. "Metabolic and cardiovascular response to exercise in patients with type 1 diabetes".
    Turinese I, Marinelli P, Bonini M, et al. · J Endocrinol Invest · 2018 · Background
    PubMed: PMID 28386795 · NCT05478707 (KML002) · Diabetes Mellitus, Type 1
  8. Physical Activity Reduces Risk of Premature Mortality in Patients With Type 1 Diabetes With and Without Kidney Disease.
    Tikkanen-Dolenc H, Wadén J, Forsblom C, et al. · Diabetes Care · 2018 · Background
    PubMed: PMID 29038314 · NCT05478707 (KML002) · Diabetes Mellitus, Type 1
  9. Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study.
    Rawshani A, Sattar N, Franzén S, et al. · Lancet · 2018 · Background
    PubMed: PMID 30129464 · NCT05478707 (KML002) · Diabetes Mellitus, Type 1
  10. Effects of the Novel Long-Acting GLP-1 Agonist, Albiglutide, on Cardiac Function, Cardiac Metabolism, and Exercise Capacity in Patients With Chronic Heart Failure and Reduced Ejection Fraction.
    Lepore JJ, Olson E, Demopoulos L, et al. · JACC Heart Fail · 2018 · Background
    PubMed: PMID 27039125 · NCT05478707 (KML002) · Diabetes Mellitus, Type 1
  11. Attitudes and barriers to exercise in adults with a recent diagnosis of type 1 diabetes: a qualitative study of participants in the Exercise for Type 1 Diabetes (EXTOD) study.
    Kennedy A, Narendran P, Andrews RC, et al. · BMJ Open · 2018 · Background
    PubMed: PMID 29371269 · NCT05478707 (KML002) · Diabetes Mellitus, Type 1
  12. Effect of once-weekly dulaglutide on glycated haemoglobin (HbA1c) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1c.
    Gallwitz B, Dagogo-Jack S, Thieu V, et al. · Diabetes Obes Metab · 2018 · Background
    PubMed: PMID 28817231 · NCT05478707 (KML002) · Diabetes Mellitus, Type 1

2017 (6 papers)

  1. Effect of Liraglutide Therapy on Liver Fat Content in Patients With Inadequately Controlled Type 2 Diabetes: The Lira-NAFLD Study.
    Petit JM, Cercueil JP, Loffroy R, et al. · J Clin Endocrinol Metab · 2017 · Trial result
    PubMed: PMID 27732328 · NCT03590626 (D-LIFT) · Diabetes Mellitus, Type 2
  2. Reduction of visceral fat by liraglutide is associated with ameliorations of hepatic steatosis, albuminuria, and micro-inflammation in type 2 diabetic patients with insulin treatment: a randomized control trial.
    Bouchi R, Nakano Y, Fukuda T, et al. · Endocr J · 2017 · Trial result
    PubMed: PMID 27916783 · NCT03590626 (D-LIFT) · Diabetes Mellitus, Type 2
  3. Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial.
    Mathieu C, Zinman B, Hemmingsson JU, et al. · Diabetes Care · 2017 · Background
    PubMed: PMID 27506222 · NCT05478707 (KML002) · Diabetes Mellitus, Type 1
  4. Liraglutide prevents microvascular insulin resistance and preserves muscle capillary density in high-fat diet-fed rats.
    Chai W, Fu Z, Aylor KW, et al. · Am J Physiol Endocrinol Metab · 2017 · Background
    PubMed: PMID 27436611 · NCT05478707 (KML002) · Diabetes Mellitus, Type 1
  5. Estimated insulin sensitivity predicts incident micro- and macrovascular complications in adults with type 1 diabetes over 6 years: the coronary artery calcification in type 1 diabetes study.
    Bjornstad P, Maahs DM, Duca LM, et al. · J Diabetes Complications · 2017 · Background
    PubMed: PMID 26936306 · NCT05478707 (KML002) · Diabetes Mellitus, Type 1
  6. Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: The ADJUNCT TWO Randomized Trial.
    Ahrén B, Hirsch IB, Pieber TR, et al. · Diabetes Care · 2017 · Background
    PubMed: PMID 27493132 · NCT05478707 (KML002) · Diabetes Mellitus, Type 1

2016 (6 papers)

  1. Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2).
    Giorgino F, Benroubi M, Sun JH, et al. · Diabetes Care · 2016 · Trial result
    PubMed: PMID 26089386 · NCT03590626 (D-LIFT) · Diabetes Mellitus, Type 2
  2. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
    Marso SP, Daniels GH, Brown-Frandsen K, et al. · N Engl J Med · 2016 · Background
    PubMed: PMID 27295427 · NCT05478707 (KML002) · Diabetes Mellitus, Type 1
  3. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
    Marso SP, Bain SC, Consoli A, et al. · N Engl J Med · 2016 · Background
    PubMed: PMID 27633186 · NCT05478707 (KML002) · Diabetes Mellitus, Type 1
  4. Clinical Pharmacokinetics of Dulaglutide in Patients with Type 2 Diabetes: Analyses of Data from Clinical Trials.
    Geiser JS, Heathman MA, Cui X, et al. · Clin Pharmacokinet · 2016 · Background
    PubMed: PMID 26507721 · NCT05459285 · Diabetes Mellitus, Type 2
  5. GLP-1 receptor agonists in type 1 diabetes: a proof-of-concept approach.
    Crisci I, Aragona M, Politi KS, et al. · Acta Diabetol · 2016 · Background
    PubMed: PMID 26293127 · NCT05478707 (KML002) · Diabetes Mellitus, Type 1
  6. Metabolic and hormonal response to intermittent high-intensity and continuous moderate intensity exercise in individuals with type 1 diabetes: a randomised crossover study.
    Bally L, Zueger T, Buehler T, et al. · Diabetologia · 2016 · Background
    PubMed: PMID 26739816 · NCT05478707 (KML002) · Diabetes Mellitus, Type 1

2015 (7 papers)

  1. Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5).
    Nauck M, Weinstock RS, Umpierrez GE, et al. · Diabetes Care · 2015 · Trial result
    PubMed: PMID 24742660 · NCT03590626 (D-LIFT) · Diabetes Mellitus, Type 2
  2. Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial).
    Loomba R, Sirlin CB, Ang B, et al. · Hepatology · 2015 · Trial result
    PubMed: PMID 25482832 · NCT03590626 (D-LIFT) · Diabetes Mellitus, Type 2
  3. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial.
    Dungan KM, Povedano ST, Forst T, et al. · Lancet · 2015 · Trial result
    PubMed: PMID 25018121 · NCT03590626 (D-LIFT) · Diabetes Mellitus, Type 2
  4. Inflammation-induced microvascular insulin resistance is an early event in diet-induced obesity.
    Zhao L, Fu Z, Wu J, et al. · Clin Sci (Lond) · 2015 · Background
    PubMed: PMID 26265791 · NCT05478707 (KML002) · Diabetes Mellitus, Type 1
  5. Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3).
    Umpierrez G, Tofé Povedano S, Pérez Manghi F, et al. · Diabetes Care · 2015 · Background
    PubMed: PMID 24842985 · NCT03590626 (D-LIFT) · Diabetes Mellitus, Type 2
  6. Insulin resistance in patients with type 1 diabetes assessed by glucose clamp studies: systematic review and meta-analysis.
    Donga E, Dekkers OM, Corssmit EP, et al. · Eur J Endocrinol · 2015 · Background
    PubMed: PMID 25899581 · NCT05478707 (KML002) · Diabetes Mellitus, Type 1
  7. GLP-1 reduces metalloproteinase-9 induced by both hyperglycemia and hypoglycemia in type 1 diabetes. The possible role of oxidative stress.
    Ceriello A, La Sala L, De Nigris V, et al. · Ther Clin Risk Manag · 2015 · Background
    PubMed: PMID 26082639 · NCT05478707 (KML002) · Diabetes Mellitus, Type 1

2014 (4 papers)

  1. GLP-1 at physiological concentrations recruits skeletal and cardiac muscle microvasculature in healthy humans.
    Subaran SC, Sauder MA, Chai W, et al. · Clin Sci (Lond) · 2014 · Background
    PubMed: PMID 24552454 · NCT05478707 (KML002) · Diabetes Mellitus, Type 1
  2. Glucagon-like peptide 1 reduces endothelial dysfunction, inflammation, and oxidative stress induced by both hyperglycemia and hypoglycemia in type 1 diabetes.
    Ceriello A, Novials A, Ortega E, et al. · Diabetes Care · 2014 · Background
    PubMed: PMID 23564922 · NCT05478707 (KML002) · Diabetes Mellitus, Type 1
  3. Vitamin C further improves the protective effect of glucagon-like peptide-1 on acute hypoglycemia-induced oxidative stress, inflammation, and endothelial dysfunction in type 1 diabetes.
    Ceriello A, Novials A, Ortega E, et al. · Diabetes Care · 2014 · Background
    PubMed: PMID 24130351 · NCT05478707 (KML002) · Diabetes Mellitus, Type 1
  4. Metformin and liraglutide ameliorate high glucose-induced oxidative stress via inhibition of PKC-NAD(P)H oxidase pathway in human aortic endothelial cells.
    Batchuluun B, Inoguchi T, Sonoda N, et al. · Atherosclerosis · 2014 · Background
    PubMed: PMID 24401231 · NCT05478707 (KML002) · Diabetes Mellitus, Type 1

2013 (3 papers)

  1. Association between novel MRI-estimated pancreatic fat and liver histology-determined steatosis and fibrosis in non-alcoholic fatty liver disease.
    Patel NS, Peterson MR, Brenner DA, et al. · Aliment Pharmacol Ther · 2013 · Trial result
    PubMed: PMID 23383649 · NCT03590626 (D-LIFT) · Diabetes Mellitus, Type 2
  2. Association of physical activity with all-cause mortality and incident and prevalent cardiovascular disease among patients with type 1 diabetes: the EURODIAB Prospective Complications Study.
    Tielemans SM, Soedamah-Muthu SS, De Neve M, et al. · Diabetologia · 2013 · Background
    PubMed: PMID 23052062 · NCT05478707 (KML002) · Diabetes Mellitus, Type 1
  3. Exenatide improves endothelial function assessed by flow mediated dilation technique in subjects with type 2 diabetes: results from an observational research.
    Irace C, De Luca S, Shehaj E, et al. · Diab Vasc Dis Res · 2013 · Background
    PubMed: PMID 22732108 · NCT05478707 (KML002) · Diabetes Mellitus, Type 1

2012 (7 papers)

  1. Correlation between liver histology and novel magnetic resonance imaging in adult patients with non-alcoholic fatty liver disease - MRI accurately quantifies hepatic steatosis in NAFLD.
    Permutt Z, Le TA, Peterson MR, et al. · Aliment Pharmacol Ther · 2012 · Trial result
    PubMed: PMID 22554256 · NCT03590626 (D-LIFT) · Diabetes Mellitus, Type 2
  2. Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: a randomized controlled trial.
    Le TA, Chen J, Changchien C, et al. · Hepatology · 2012 · Trial result
    PubMed: PMID 22431131 · NCT03590626 (D-LIFT) · Diabetes Mellitus, Type 2
  3. Defining insulin resistance from hyperinsulinemic-euglycemic clamps.
    Tam CS, Xie W, Johnson WD, et al. · Diabetes Care · 2012 · Background
    PubMed: PMID 22511259 · NCT05478707 (KML002) · Diabetes Mellitus, Type 1
  4. Muscle microvascular recruitment predicts insulin sensitivity in middle-aged patients with type 1 diabetes mellitus.
    Chan A, Barrett EJ, Anderson SM, et al. · Diabetologia · 2012 · Background
    PubMed: PMID 22167126 · NCT05478707 (KML002) · Diabetes Mellitus, Type 1
  5. Features of hepatic and skeletal muscle insulin resistance unique to type 1 diabetes.
    Bergman BC, Howard D, Schauer IE, et al. · J Clin Endocrinol Metab · 2012 · Background
    PubMed: PMID 22362823 · NCT05478707 (KML002) · Diabetes Mellitus, Type 1
  6. LY2189265, a long-acting glucagon-like peptide-1 analogue, showed a dose-dependent effect on insulin secretion in healthy subjects.
    Barrington P, Chien JY, Tibaldi F, et al. · Diabetes Obes Metab · 2012 · Background
    PubMed: PMID 21251179 · NCT05459285 · Diabetes Mellitus, Type 2
  7. A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes.
    Barrington P, Chien JY, Showalter HD, et al. · Diabetes Obes Metab · 2012 · Background
    PubMed: PMID 21251178 · NCT05459285 · Diabetes Mellitus, Type 2

2011 (3 papers)

  1. Assessment of flow-mediated dilation in humans: a methodological and physiological guideline.
    Thijssen DH, Black MA, Pyke KE, et al. · Am J Physiol Heart Circ Physiol · 2011 · Background
    PubMed: PMID 20952670 · NCT05478707 (KML002) · Diabetes Mellitus, Type 1
  2. Endothelial dysfunction is related to poor glycemic control in adolescents with type 1 diabetes under 5 years of disease: evidence of metabolic memory.
    Cé GV, Rohde LE, da Silva AM, et al. · J Clin Endocrinol Metab · 2011 · Background
    PubMed: PMID 21346068 · NCT05478707 (KML002) · Diabetes Mellitus, Type 1
  3. Insulin regulates its own delivery to skeletal muscle by feed-forward actions on the vasculature.
    Barrett EJ, Wang H, Upchurch CT, et al. · Am J Physiol Endocrinol Metab · 2011 · Background
    PubMed: PMID 21610226 · NCT05478707 (KML002) · Diabetes Mellitus, Type 1

2010 (2 papers)

  1. Cause-specific mortality trends in a large population-based cohort with long-standing childhood-onset type 1 diabetes.
    Secrest AM, Becker DJ, Kelsey SF, et al. · Diabetes · 2010 · Background
    PubMed: PMID 20739685 · NCT05478707 (KML002) · Diabetes Mellitus, Type 1
  2. Prediction of future cardiovascular outcomes by flow-mediated vasodilatation of brachial artery: a meta-analysis.
    Inaba Y, Chen JA, Bergmann SR, et al. · Int J Cardiovasc Imaging · 2010 · Background
    PubMed: PMID 20339920 · NCT05478707 (KML002) · Diabetes Mellitus, Type 1

2009 (2 papers)

  1. Protein expression in vascular endothelial cells obtained from human peripheral arteries and veins.
    Silver AE, Christou DD, Donato AJ, et al. · J Vasc Res · 2009 · Background
    PubMed: PMID 19672102 · NCT05478707 (KML002) · Diabetes Mellitus, Type 1
  2. Insulin is a stronger inducer of insulin resistance than hyperglycemia in mice with type 1 diabetes mellitus (T1DM).
    Liu HY, Cao SY, Hong T, et al. · J Biol Chem · 2009 · Background
    PubMed: PMID 19654321 · NCT05478707 (KML002) · Diabetes Mellitus, Type 1

2007 (1 paper)

  1. Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride.
    Basu A, Charkoudian N, Schrage W, et al. · Am J Physiol Endocrinol Metab · 2007 · Background
    PubMed: PMID 17711996 · NCT05478707 (KML002) · Diabetes Mellitus, Type 1

2006 (1 paper)

  1. Obesity blunts insulin-mediated microvascular recruitment in human forearm muscle.
    Clerk LH, Vincent MA, Jahn LA, et al. · Diabetes · 2006 · Background
    PubMed: PMID 16644702 · NCT05478707 (KML002) · Diabetes Mellitus, Type 1

2005 (1 paper)

  1. Aerobic exercise capacity in normal adolescents and those with type 1 diabetes mellitus.
    Komatsu WR, Gabbay MA, Castro ML, et al. · Pediatr Diabetes · 2005 · Background
    PubMed: PMID 16109070 · NCT05478707 (KML002) · Diabetes Mellitus, Type 1

2004 (1 paper)

  1. Microvascular recruitment is an early insulin effect that regulates skeletal muscle glucose uptake in vivo.
    Vincent MA, Clerk LH, Lindner JR, et al. · Diabetes · 2004 · Background
    PubMed: PMID 15161743 · NCT05478707 (KML002) · Diabetes Mellitus, Type 1

2002 (1 paper)

  1. Biopsy coupled to quantitative immunofluorescence: a new method to study the human vascular endothelium.
    Colombo PC, Ashton AW, Celaj S, et al. · J Appl Physiol (1985) · 2002 · Background
    PubMed: PMID 11842075 · NCT05478707 (KML002) · Diabetes Mellitus, Type 1

1998 (1 paper)

  1. Quantification of myocardial blood flow with ultrasound-induced destruction of microbubbles administered as a constant venous infusion.
    Wei K, Jayaweera AR, Firoozan S, et al. · Circulation · 1998 · Background
    PubMed: PMID 9490243 · NCT05478707 (KML002) · Diabetes Mellitus, Type 1

1992 (1 paper)

  1. Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus.
    Gutniak M, Orskov C, Holst JJ, et al. · N Engl J Med · 1992 · Background
    PubMed: PMID 1348845 · NCT05478707 (KML002) · Diabetes Mellitus, Type 1

Sources and methodology

This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).